Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GenVec announces plans for HIV vaccine trials
These will be the first human trials to assess the effectiveness of a ‘prime-boost’ vaccine using GenVec’s adenovector technology as a potential therapy for patients infected with HIV.
These will be the first human trials to assess the effectiveness of a ‘prime-boost’ vaccine using GenVec’s adenovector technology as a potential therapy for patients infected with HIV.
Auriga is developing an oral, controlled-release corticosteroid formulation that targets inflammatory bowel disease lesions at different sites within the gastrointestinal (GI) tract. Under the terms of the development
Flurizan is the first in a new class of investigative drugs known as selective amyloid lowering agents, or SALAs. This mechanism is different from the currently marketed drugs
Protalix has developed and patented a unique plant cell culture platform and bioreactor system that provides an efficient, easily scaleable and cost-effective system for the expression of human
The companies plan to use Medarex’ UltiMAb Human Antibody Development system to generate antibodies to novel disease targets provided by GenPat77. This technology can be used to help
Neuren’s phase IIa clinical trial investigated the safety, tolerability and pharmacokinetics of a four-hour infusion of Glypromate in 33 cardiac surgery patients. Of these, 12 patients received 3mg/kg/hr,
This trial is designed to identify the dose or doses of methylnaltrexone to be taken forward into the phase III clinical studies that will evaluate the efficacy, safety
The UC Davis study, which was co-authored by an international team that included scientists from the University of Hong Kong and Johns Hopkins University, has been published in
Under the terms of the agreement, Novartis will provide R&D funding and Entelos will conduct biosimulation research using its PhysioLab platforms, which predict the effects of drugs using
About half of women whose breast cancer is treated with standard chemotherapy have their cancer return within five years. Furthermore, most chemotherapeutic drugs have undesirable side effects, but